Should I buy or sell biote stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for biote in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTMD shares. View BTMD analyst ratings or view top-rated stocks .

What is biote's stock price target for 2024?

5 brokers have issued 12-month price targets for biote's stock. Their BTMD share price targets range from $6.55 to $9.00. On average, they anticipate the company's share price to reach $8.11 in the next year. This suggests a possible upside of 40.1% from the stock's current price. View analysts price targets for BTMD or view top-rated stocks among Wall Street analysts .

How have BTMD shares performed in 2024?

biote's stock was trading at $4.94 on January 1st, 2024. Since then, BTMD shares have increased by 17.2% and is now trading at $5.79. View the best growth stocks for 2024 here .

Are investors shorting biote?

biote saw a increase in short interest in March. As of March 31st, there was short interest totaling 878,200 shares, an increase of 16.4% from the March 15th total of 754,400 shares. Based on an average daily volume of 117,500 shares, the short-interest ratio is currently 7.5 days. Currently, 2.6% of the shares of the stock are short sold. View biote's Short Interest .

When is biote's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BTMD earnings forecast .

How were biote's earnings last quarter?

biote Corp. (NASDAQ:BTMD) issued its quarterly earnings data on Tuesday, March, 12th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.06. The company earned $45.70 million during the quarter, compared to analyst estimates of $45.50 million. biote had a negative trailing twelve-month return on equity of 45.10% and a net margin of 1.79%.

What guidance has biote issued on next quarter's earnings?

biote issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million.

How do I buy shares of biote?

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BTMD

biote (BTMD) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free BTMD Stock Alerts

$5.79

-0.10 (-1.70%)

(As of 03:34 PM ET)

Compare

Today's Range: $5.79
▼
$5.94
50-Day Range: $3.97
▼
$6.91
52-Week Range: $3.65
▼
$8.22

Volume: 46,035 shs
Average Volume: 112,187 shs
Market Capitalization: $431.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.11

Get biote alerts:

biote MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 40.1% Upside
$8.11 Price Target
Short Interest: Bearish
2.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.07
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 53.85%
From $0.39 to $0.60 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

416th out of 930 stocks

Medicinals & Botanicals Industry

3rd out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
biote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
biote has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.64% of the float of biote has been sold short.
Short Interest Ratio / Days to Cover
biote has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in biote has recently increased by 16.41%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
biote does not currently pay a dividend.
Dividend Growth
biote does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BTMD.

3.4

News and Social Media Coverage

News Sentiment
biote has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for biote this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added biote to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, biote insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.00% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.68% of the stock of biote is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for biote are expected to grow by 53.85% in the coming year, from $0.39 to $0.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of biote is -26.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of biote is -26.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About biote Stock (NASDAQ:BTMD)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

BTMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BTMD Stock News Headlines

April 8, 2024 | americanbankingnews.com

B. Riley Weighs in on biote Corp.'s Q1 2024 Earnings (NASDAQ:BTMD)

March 25, 2024 | msn.com

Esperion stock jumps 18% in wake of FDA label expansions

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

March 18, 2024 | markets.businessinsider.com

Pharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial Prospects

March 14, 2024 | marketwatch.com

Biote Soars 22% With Expected Acceleration in 2H 2024 Sales

March 13, 2024 | finance.yahoo.com

biote Corp. (PNK:BTMD) Q4 2023 Earnings Call Transcript

March 12, 2024 | finance.yahoo.com

Biote Corp (BTMD) Reports Growth Amidst Challenges in Q4 and Full Year 2023

March 12, 2024 | businesswire.com

Biote Reports Fourth Quarter and Full Year 2023 Financial Results

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 11, 2024 | benzinga.com

Preview: Biote's Earnings

February 27, 2024 | finance.yahoo.com

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

February 27, 2024 | businesswire.com

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

February 20, 2024 | msn.com

Biote announces agreement to resolve litigation with founder Gary Donovitz

February 20, 2024 | finance.yahoo.com

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares

February 20, 2024 | businesswire.com

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares

January 25, 2024 | finance.yahoo.com

Biote Announces $20 Million Share Repurchase Authorization

January 20, 2024 | benzinga.com

Biote Stock (NASDAQ:BTMD), Analyst Ratings, Price Targets, Predictions

January 18, 2024 | bizjournals.com

Birmingham manufacturer to be acquired for $8.5M

January 18, 2024 | realmoney.thestreet.com

Biote price target lowered by $1 at Truist, here's why

January 11, 2024 | msn.com

Biote names Robert Peterson as its CFO

January 11, 2024 | markets.businessinsider.com

Biote Names Robert Peterson CFO

January 11, 2024 | finance.yahoo.com

Biote Names Robert Peterson as Chief Financial Officer

November 30, 2023 | seekingalpha.com

biote Should Keep Delivering Strong Growth

November 8, 2023 | msn.com

Durect, Lumos Pharma among healthcare movers

November 8, 2023 | msn.com

BIOTE GAAP EPS of $0.24, revenue of $45.6M

November 8, 2023 | finance.yahoo.com

Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates

November 7, 2023 | finance.yahoo.com

Biote Reports Third Quarter 2023 Financial Results

See More Headlines

Receive BTMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medicinals & botanicals
Sub-Industry: N/A
Current Symbol: NASDAQ:BTMD
CUSIP: N/A
CIK: 1819253
Web: biote.com
Phone: 844-604-1246
Fax: 212-616-9601
Employees: 194
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.11
High Stock Price Target: $9.00
Low Stock Price Target: $6.55
Potential Upside/Downside: +37.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 15.10
P/E Growth: N/A
Net Income: $3.32 million
Net Margins: 1.79%
Pretax Margin: -0.07%
Return on Equity: -45.10%
Return on Assets: 19.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.51
Quick Ratio: 4.73

Sales & Book Value

Annual Sales: $185.36 million
Price / Sales: 2.37
Cash Flow: $0.49 per share
Price / Cash Flow: 12.09
Book Value: ($0.58) per share
Price / Book: -10.16

Miscellaneous

Outstanding Shares: 74,530,000
Free Float: 59,626,000
Market Cap: $438.98 million
Optionable: Not Optionable
Beta: 0.87

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Marc D. Beer (Age 59)
Executive Chairman
Comp: $484k
Ms. Teresa S. Weber (Age 71)
CEO & Director
Comp: $3.7M
Ms. Mary Elizabeth Conlon (Age 43)
VP of Business Development, General Counsel & Corporate Secretary
Comp: $475k
Mr. Robert Peterson
Chief Financial Officer
Mr. Joe Butler (Age 62)
Chief Information Officer
Mr. James Elliott Gibbs II
Chief People Officer
Mr. Richard Kevin Key (Age 53)
Chief Digital Officer
Mr. Jade Beutler (Age 61)
Head of Nutraceuticals
Dr. Ross W. McQuivey M.D. (Age 52)
Chief Medical Officer & Member of Medical Advisory Board
Dr. Cory Rice D.O.
Chief Clinical Advisor & Member of Medical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTMD Stock Analysis - Frequently Asked Questions

Should I buy or sell biote stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for biote in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTMD shares.
View BTMD analyst ratings or view top-rated stocks.
What is biote's stock price target for 2024?: 5 brokers have issued 12-month price targets for biote's stock. Their BTMD share price targets range from $6.55 to $9.00. On average, they anticipate the company's share price to reach $8.11 in the next year. This suggests a possible upside of 40.1% from the stock's current price.
View analysts price targets for BTMD or view top-rated stocks among Wall Street analysts.
How have BTMD shares performed in 2024?: biote's stock was trading at $4.94 on January 1st, 2024. Since then, BTMD shares have increased by 17.2% and is now trading at $5.79.
View the best growth stocks for 2024 here.
Are investors shorting biote?: biote saw a increase in short interest in March. As of March 31st, there was short interest totaling 878,200 shares, an increase of 16.4% from the March 15th total of 754,400 shares. Based on an average daily volume of 117,500 shares, the short-interest ratio is currently 7.5 days. Currently, 2.6% of the shares of the stock are short sold.
View biote's Short Interest.

When is biote's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BTMD earnings forecast.
How were biote's earnings last quarter?: biote Corp. (NASDAQ:BTMD) issued its quarterly earnings data on Tuesday, March, 12th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.06. The company earned $45.70 million during the quarter, compared to analyst estimates of $45.50 million. biote had a negative trailing twelve-month return on equity of 45.10% and a net margin of 1.79%.
What guidance has biote issued on next quarter's earnings?: biote issued an update on its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $203.2 million.
How do I buy shares of biote?: Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTMD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial